Skip to main content

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M

Publication: Ann Oncol (2009) • Vol 20 • Page 1948-52PMID: 19570962View on PubMed

Purpose

The purpose of this paper was to determine the effects of using core needle biopsies (CNB) as opposed to excisional biopsies (EB) for the determination of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in early breast cancer specimens.

Conclusion

ER status was concordant between CNB and EB from the same tumor 98.2% of the time. PR status showed concordance between CNB and EB only 85% of the time with almost equal division between CNB+/EB- and CNB-/EB+ cases. HER2 status showed concordance between CNB and EB 98.8% of the time. The authors recommend against using CNB for PR status determination, but CNB was deemed acceptable for ER and HER2 status determination.

Studies (1)

Purpose

The purpose of this study was to determine the effects of using CNB as opposed to EB for ER, PR, and HER2 status determination in early breast cancer specimens. The median time between collection of a CNB specimen and collection of an EB from the same patient was 27 days. Specimens were preserved in neutral buffered saline.

Summary of Findings

ER status was concordant between CNB and EB from the same tumor 98.2% of the time and showed discrepancy in 6 out of 336 paired specimens. In 5/6 of these cases, the positive ER score was borderline or modestly positive. PR status was concordant between CNB and EB only 85% of the time with almost equal division between CNB+/EB- and CNB-/EB+ cases. HER2 status was concordant between CNB and EB 98.8% of the time. In the four discrepant cases, 3 were CNB-/EB+ and 1 was CNB+/EB-. In the CNB positive specimen, FISH showed amplification between 2.0 and 3.0 indicating only low level amplification. The authors recommend against using CNB for PR status determination but deemed the use of CNB for ER and HER2 status determination acceptable.

  • Biospecimens

    TissueBreast
  • Preservation Types

    Other Preservative
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
    DNAFISH
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionMethod of tissue acquisition
    Core needle biopsy
    Excisional biopsy
    FISH SpecificTargeted nucleic acid
    HER2
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER2
    PR